Drug Trial Radar · NCT02369978
CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)
Last checked: Nov 20, 2026Latest source record: Jul 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
500
Planned (sponsor's estimate)
Start
Aug 2015
Primary completion
Aug 2018
Study completion Feb 2019
Sponsor
- Lead sponsor
- Universidad Autónoma de BucaramangaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Fundación Cardioinfantil Instituto de Cardiología; Instituto Nacional de Salud, Colombia; Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben
- First posted
- Feb 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, blind, parallel-group trial will evaluate the efficacy and safety of Nifurtimox (NFX) and Benznidazole (BZN), the two usual interventions to treat the parasite Trypanosoma cruzi. The investigators will test whether NFX is an effective trypanocidal agent (by comparison with placebo) and equivalent to BZN (as active comparator) in terms of both parasite-related and safety outcomes. Individuals found seropositive and without clinical signs of dilated cardiomyopathy will receive either of the active treatments or matching placebo. Participants allocated to NFX or BZN will receive either a 60-day (full-dose) or a 120-day (half-dose) active treatment, whereas the control group will receive placebo for 120 days. There will be thus four arms of active treatment (NFX60, NFX120, BZN60 and BZN120), and a fifth control arm receiving placebo (1:1:1:1:1 allocation ratio) where every participant in the trial will take 120 days of study drug (the groups receiving full-dose will complete a 120-day masked treatment with placebo). The study plans to enroll 500 participants from Colombia (in two different geographical areas) and Argentina, in order to explore regional differences in the treatment effects.
Conditions
- Chagas Disease
Interventions
NifurtimoxDrug
Full dose: 8 mg/Kg/day, assuming an average weight of 60 Kg: 240 mg B.I.D Half-dose: 120 mg B.I.D
BenznidazoleDrug
Full dose: 5 mg/Kg/day, assuming an average weight of 60 Kg: 150 mg B.I.D Half dose: 75 mg B.I.D
PlaceboDrug
Two capsules of matching placebo (contaning Magnesium stearate and cellulose) B.I.D
Primary outcomes
What the sponsor says the trial is designed to measure.
- Quantitative Polymerase Chain Reaction (qPCR) for Trypanosoma cruziTime frame: 12 - 18 months after starting therapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fundación Oftalmológica de Santander - Clínica Ardila Lulle (FOSCAL)
Bucaramanga, Santander Department, Colombia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.